Vivani Medical Inc. (VANI) - Net Assets
Based on the latest financial reports, Vivani Medical Inc. (VANI) has net assets worth $15.73 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($39.39 Million) and total liabilities ($23.66 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check VANI intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $15.73 Million |
| % of Total Assets | 39.93% |
| Annual Growth Rate | N/A |
| 5-Year Change | 538.13% |
| 10-Year Change | 41.08% |
| Growth Volatility | 495.83 |
Vivani Medical Inc. - Net Assets Trend (2012–2025)
This chart illustrates how Vivani Medical Inc.'s net assets have evolved over time, based on quarterly financial data. See Vivani Medical Inc. (VANI) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Vivani Medical Inc. (2012–2025)
The table below shows the annual net assets of Vivani Medical Inc. from 2012 to 2025. For live valuation and market cap data, see VANI stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $15.73 Million | -10.68% |
| 2024-12-31 | $17.61 Million | -15.18% |
| 2023-12-31 | $20.76 Million | -53.14% |
| 2022-12-31 | $44.31 Million | +1697.48% |
| 2021-12-31 | $2.46 Million | +26.41% |
| 2020-12-31 | $1.95 Million | -73.20% |
| 2019-12-31 | $7.28 Million | +135.89% |
| 2018-12-31 | $3.08 Million | -60.87% |
| 2017-12-31 | $7.88 Million | -29.31% |
| 2016-12-31 | $11.15 Million | -44.99% |
| 2015-12-31 | $20.27 Million | -41.45% |
| 2014-12-31 | $34.62 Million | +475.43% |
| 2013-12-31 | $-9.22 Million | -202.94% |
| 2012-12-31 | $-3.04 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Vivani Medical Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5403920400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $8.00K | 0.05% |
| Other Comprehensive Income | $30.00K | 0.19% |
| Other Components | $164.22 Million | 1044.02% |
| Total Equity | $15.73 Million | 100.00% |
Vivani Medical Inc. Competitors by Market Cap
The table below lists competitors of Vivani Medical Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CFI Holding SA
WAR:CFI
|
$99.18 Million |
|
Kuen Ling Refrigerating Machinery Co Ltd
TWO:4527
|
$99.21 Million |
|
Bunzl PLC
LSE:BNZL
|
$99.29 Million |
|
Jiayin Group Inc
NASDAQ:JFIN
|
$99.29 Million |
|
Ferronordic AB (publ)
ST:FNM
|
$99.15 Million |
|
STARPHARMA HLDG.SP.ADR/10
F:PQ6A
|
$99.13 Million |
|
New Horizon Aircraft Ltd
NASDAQ:HOVR
|
$99.13 Million |
|
Intelligent Digital Integrated Security Co. Ltd
KQ:143160
|
$99.05 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vivani Medical Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 17,610,000 to 15,730,000, a change of -1,880,000 (-10.7%).
- Net loss of 26,609,000 reduced equity.
- Share repurchases of 28,000 reduced equity.
- New share issuances of 23,291,000 increased equity.
- Other comprehensive income decreased equity by 18,000.
- Other factors increased equity by 1,484,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-26.61 Million | -169.16% |
| Share Repurchases | $28.00K | -0.18% |
| Share Issuances | $23.29 Million | +148.07% |
| Other Comprehensive Income | $-18.00K | -0.11% |
| Other Changes | $1.48 Million | +9.43% |
| Total Change | $- | -10.68% |
Book Value vs Market Value Analysis
This analysis compares Vivani Medical Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.56x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-0.65 | $1.15 | x |
| 2013-12-31 | $-1.95 | $1.15 | x |
| 2014-12-31 | $10.14 | $1.15 | x |
| 2015-12-31 | $4.14 | $1.15 | x |
| 2016-12-31 | $2.01 | $1.15 | x |
| 2017-12-31 | $1.11 | $1.15 | x |
| 2018-12-31 | $0.36 | $1.15 | x |
| 2019-12-31 | $0.47 | $1.15 | x |
| 2020-12-31 | $0.07 | $1.15 | x |
| 2021-12-31 | $0.07 | $1.15 | x |
| 2022-12-31 | $1.16 | $1.15 | x |
| 2023-12-31 | $0.41 | $1.15 | x |
| 2024-12-31 | $0.32 | $1.15 | x |
| 2025-12-31 | $0.25 | $1.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vivani Medical Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -169.16%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.50x
- Recent ROE (-169.16%) is above the historical average (-279.35%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | -1190.67% | 0.17x | 0.00x | $-15.97 Million |
| 2013 | 0.00% | -1467.73% | 0.12x | 0.00x | $-22.05 Million |
| 2014 | -101.68% | -1035.99% | 0.08x | 1.24x | $-38.66 Million |
| 2015 | -98.77% | -223.66% | 0.32x | 1.39x | $-22.04 Million |
| 2016 | -297.57% | -832.60% | 0.24x | 1.51x | $-34.29 Million |
| 2017 | -361.79% | -358.06% | 0.55x | 1.84x | $-29.30 Million |
| 2018 | -1137.94% | -508.90% | 0.65x | 3.46x | $-35.40 Million |
| 2019 | -461.75% | -994.14% | 0.20x | 2.28x | $-34.32 Million |
| 2020 | -475.85% | -927900.00% | 0.00x | 2.68x | $-9.47 Million |
| 2021 | -518.17% | -4912692.31% | 0.00x | 2.21x | $-13.02 Million |
| 2022 | -31.35% | 0.00% | 0.00x | 1.15x | $-18.32 Million |
| 2023 | -123.56% | 0.00% | 0.00x | 2.21x | $-27.73 Million |
| 2024 | -133.37% | 0.00% | 0.00x | 2.36x | $-25.25 Million |
| 2025 | -169.16% | 0.00% | 0.00x | 2.50x | $-28.18 Million |
Industry Comparison
This section compares Vivani Medical Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vivani Medical Inc. (VANI) | $15.73 Million | 0.00% | 1.50x | $99.17 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Vivani Medical Inc.
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the t… Read more